Comprehensive Study of Chromosomal Copy Number Variations and Genomic Variations Predicting Overall Survival in Myelodysplastic Syndromes
Oncology · 2024
DOI: 10.1159/000536446 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology, 2024. Verfasst von Nehakumari Maurya und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cytogenetics, ICMR-National Institute of Immunohaematology, Mumbai, India. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Polymorphism, Single Nucleotide, DNA Copy Number Variations, High-Throughput Nucleotide Sequencing. Die Arbeit nennt 26 Literaturangaben.
Abstract (Originalsprache)
Introduction
Myelodysplastic syndrome (MDS) is a heterogeneous disease characterized by cytopenia, marrow dysplasia and has a propensity to develop into acute myeloid leukemia. The disease progression is majorly affected by genetic defects. However, about 40–50% of patients with MDS present with a normal karyotype and develop different courses of disease. Hence, there remains a room to advance the biological understanding and find molecular prognostic markers for cytogenetically normal MDS.
Methods
We performed a high-resolution CGH + SNP array along with next-generation sequencing (NGS) of 77 primary diagnosed MDS patients, and also they were clinically followed up.
Results
Our study revealed 82 clinically significant genomic lesions (losses/gains) in 49% of MDS patients. CGH + SNP array reduced the proportion of normal karyotype by 30%. SNP array in combination with NGS confirmed the biallelic loss of function of the TP53 gene (2/6), which is a clinically relevant biomarker and new genetic-based MDS entity, i.e., MDS-biTP53, as per the new WHO classification 2022. Genomic region 2p22.3 presented with frequent lesions and also with a more hazard ratio (2.7, 95% CI: 0.37–21) when analyzed by Kaplan-Meier survival analysis.
Conclusion
CGH + SNP array changed the cytogenetic and IPSS-R risk group in 18% and 13% of patients, respectively, with an improved prediction of prognosis. This study emphasizes the cytogenetic heterogeneity of MDS and highlights that abnormality with chromosome 2 may have a diagnostic and prognostic impact.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cytogenetics, ICMR-National Institute of Immunohaematology, Mumbai, India.
- Department of Haematology, KEM Hospital, Mumbai, India.
Zitieren
APA
Maurya, N., Shanmukhaiah, C., Dhangar, S., Madkaikar, M., & Vundinti, B. R. (2024). Comprehensive Study of Chromosomal Copy Number Variations and Genomic Variations Predicting Overall Survival in Myelodysplastic Syndromes. Oncology. https://doi.org/10.1159/000536446
Vancouver
Maurya N, Shanmukhaiah C, Dhangar S, Madkaikar M, Vundinti BR. Comprehensive Study of Chromosomal Copy Number Variations and Genomic Variations Predicting Overall Survival in Myelodysplastic Syndromes. Oncology. 2024. doi:10.1159/000536446
BibTeX
@article{Maurya2024,
author = {Maurya, Nehakumari and Shanmukhaiah, Chandrakala and Dhangar, Somprakash and Madkaikar, Manisha and Vundinti, Babu Rao},
title = {Comprehensive Study of Chromosomal Copy Number Variations and Genomic Variations Predicting Overall Survival in Myelodysplastic Syndromes},
journal = {Oncology},
year = {2024},
doi = {10.1159/000536446}
}
EUVIMED